2024 340B Oversight Hearing

Oversight And Investigations Subcommittee Hearing: “Oversight Of 340B Drug Pricing Program”

A 340B Congressional hearing held on June 4th, 2024 featured both critics and advocates of the 340B program. The hearing, conducted by the House Energy & Commerce Oversight and Investigations Subcommittee, included Dr. Anthony DiGiorgio, a neurosurgeon at the University of California San Francisco (UCSF) Health and the Zuckerberg San Francisco Hospital and Trauma Center, who criticized 340B’s growth among hospitals, as well as the leader of an Ohio-based health system who supports hospitals in the program. Critics argue that the program needs reform, while advocates emphasize its importance in supporting underserved communities.

Click Here For Audi Only  

Click below for the full video of the hearing.


The 340B Drug Pricing Program is managed by the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA). For more information visit: This material is provided for general informational purposes of 340B Drug Prices only and is not an endorsement of any prescription product referenced herein. For information as to the clinical use or efficacy of a referenced product, please contact the manufacturer. 340B Price Guide makes no representations and provides no warranties as to the effectiveness or suitability for use of any prescription product referenced herein. Any referenced cost is provided as an estimate only and the actual cost is subject to change at any time and without notice. 340B Price Guide does not guarantee that the cost represented herein will be the actual and pharmacy shall at all times collect amounts due as indicated at the time of adjudication and shall be reimbursed per the terms of its agreement.'